The Worldwide Inhalable Drugs Industry is Expected to Reach $49.47 Billion by 2027: Players Include AptarGroup, AstraZeneca, Cipla, GEA and GSK

Rhea-AI Summary

The Global Inhalable Drugs Market is projected to grow from USD 35.11 billion in 2022 to USD 49.47 billion by 2027, with a CAGR of 7.1%. The report highlights key drivers such as the rising incidence of respiratory diseases and enhanced healthcare infrastructure. Additionally, it examines challenges, including strict regulations for drug approval. Opportunities exist within the development of inhalable drugs and reformulating non-inhaled molecules. The Competitive Quadrant and Ansoff Matrix analyses offer strategic insights for market players. This comprehensive report includes an in-depth market analysis and regulatory scenarios affecting industry dynamics.

Positive

• Market expected to grow from USD 35.11 billion in 2022 to USD 49.47 billion by 2027.
• CAGR of 7.1% indicates strong growth potential in the inhalable drugs sector.
• Rising incidence of respiratory diseases presents ongoing demand.
• Emerging development of inhalable formulations increases opportunities for innovation.

Negative

• Strict regulations for approval of inhalable drugs could impede market entry.
• Availability of unregulated and alternative therapies may challenge market growth.

DUBLIN, Feb. 27, 2023 /PRNewswire/ -- The "Global Inhalable Drugs Market (2022-2027) by Product, Application, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Inhalable Drugs Market is estimated to be USD 35.11 Bn in 2022 and is expected to reach USD 49.47 Bn by 2027, growing at a CAGR of 7.1%

Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding growth and reducing risks.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global Inhalable Drugs Market. Ansoff Matrix, also known as the Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

The analyst analyses the Global Inhalable Drugs Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Why buy this report?

• The report offers a comprehensive evaluation of the Global Inhalable Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
• The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
• The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
• The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
• The report also contains a competitive analysis using Positioning Quadrants, the analyst's competitive positioning tool.

Market Dynamics

Drivers

• Rising Incidence of Respiratory Diseases Such as Chronic Obstructive Pulmonary Diseases and Asthma
• Increasing Healthcare Infrastructure and Rising Awareness among Patients
• Surge in the Number of Non-respiratory Diseases Such as Parkinson's Disease

Restraints

• Strict Regulations for the Approval of Inhalable Drugs

Opportunities

• Surge in Development of Inhalable Drugs for Ease of Administration
• Emerging Reformulation of Current Non-inhaled Molecules into Inhaled Molecules for Improved Drug Delivery

Challenges

• Availability of Unregulated and Alternate Therapy

Market Segmentation

The Global Inhalable Drugs Market is segmented based on Product, Application, and Geography.

• By Product, the market is classified into Aerosol, Dry Powder Formulation, and Spray.
• By Application, the market is classified into Non-Respiratory Diseases and Respiratory Diseases.
• By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific.

Companies Mentioned

• Adherium, Ltd.
• AptarGroup, Inc.
• AstraZeneca, PLC
• Avalyn Pharma, Inc.
• Boehringer Ingelheim International GmbH
• Cipla, Inc.
• GEA Group Ag
• GSK, PLC
• Merck & Co., Inc.
• Mundipharma International, Ltd.
• Novartis Ag
• Orion Corp
• Pfizer, Inc.
• PureIMS B.V.
• Respira Therapeutics, Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries, Ltd.
• TFF Pharmaceuticals, Inc.
• Vectura Group, Ltd.
• Verona Pharma, PLC

For more information about this report visit https://www.researchandmarkets.com/r/2oi9my-inhalable?w=5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/the-worldwide-inhalable-drugs-industry-is-expected-to-reach-49-47-billion-by-2027-players-include-aptargroup-astrazeneca-cipla-gea-and-gsk-301757127.html

SOURCE Research and Markets

FAQ

What is the forecast for the Global Inhalable Drugs Market by 2027?

The market is expected to reach USD 49.47 billion by 2027.

What is the estimated market size for inhalable drugs in 2022?

The market size for inhalable drugs is estimated at USD 35.11 billion in 2022.

What is the expected CAGR for the inhalable drugs market?

The expected CAGR for the inhalable drugs market is 7.1%.

What are the key drivers for the growth of the inhalable drugs market?

Key drivers include the rising incidence of respiratory diseases and increasing healthcare infrastructure.

What challenges does the inhalable drugs market face?

Challenges include strict regulations for drug approval and the availability of unregulated therapies.